Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Trial details
- Registry ID
- NCT04390399
- Phase
- Phase 2
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerNCT04390399 | IBRX | Phase 2 | Active not recruiting | 2025-10-13Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |